Neurologic Symptoms as a Feature of the Antiphospholipid Syndrome

 

 Buy Article Permissions and Reprints

ABSTRACT

Antiphospholipid antibodies may cause various neurologic diseases by vascular and immune mechanisms. Ischemic stroke and transient ischemic attacks are the most common neurologic complications in patients with antiphospholipid antibodies but migraine, epilepsy, chorea, or multiple sclerosis also may occur. Although the neurologic presentation of patients with the antiphospholipid syndrome may vary, many patients have striking similarities, such as initial memory loss, aphasia, cognitive dysfunction with progressive cerebral deterioration, and even dementia. In conclusion, antiphospholipid syndrome may constitute a treatable cause of neurologic diseases, and the measurement of antiphospholipid antibodies should be routinely performed in patients with neurologic disorders.

REFERENCES

• 1 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome.  J Thromb Haemost. 2006;  4 295-306
  CrossrefPubMedGoogle Scholar
• 2 Harris E N, Gharavi A E, Asherson R A et al.. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies.  Clin Exp Rheumatol. 1984;  2 47-51
  PubMedGoogle Scholar
• 3 Ferro D, Quintarelli C, Rasura M et al.. Lupus anticoagulant and the fibrinolytic system in young patients with stroke.  Stroke. 1993;  24 368-370
  PubMedGoogle Scholar
• 4 Tietjen G E, Levine S R, Brown E et al.. Factors that predict antiphospholipid immunoreactivity in young people with transient focal neurological events.  Arch Neurol. 1993;  50 833-836
  PubMedGoogle Scholar
• 5 Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The antiphospholipid antibodies in stroke study (APASS) group.  Neurology. 1993;  43 2069-2073
  PubMedGoogle Scholar
• 6 Muir K W, Squire I B, Alwan W et al.. Anticardiolipin antibodies in an unselected stroke population.  Lancet. 1994;  344 452-456
  CrossrefPubMedGoogle Scholar
• 7 Munoz-Rodriguez F J, Font J, Cervera R et al.. Clinical study and follow-up of 100 patients with antiphospholipid syndrome.  Semin Arthritis Rheum. 1999;  29 182-189
  CrossrefPubMedGoogle Scholar
• 8 Sanna G, Bertolaccini M L, Cuadrado M J et al.. Neuropsychiatric manifestations in systemic lupus erythematosus: prevelance and association with antiphospholipid antibodies.  J Rheumatol. 2003;  30 985-992
  PubMedGoogle Scholar
• 9 Janardhan V, Wolf P A, Kase C S et al.. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack. The Framingham cohort and offspring study.  Stroke. 2004;  35 736-741
  CrossrefPubMedGoogle Scholar
• 10 Jara L J, Medina G, Vera-Lastra O et al.. Atherosclerosis and antiphospholipid syndrome.  Clin Rev Allergy Immunol. 2003;  25 79-88
  PubMedGoogle Scholar
• 11 Medina G, Casaos D, Jara L J et al.. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome.  Ann Rheum Dis. 2003;  62 607-610
  CrossrefPubMedGoogle Scholar
• 12 Levine S R, Brey R L, Sawaya K L et al.. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.  Ann Neurol. 1995;  38 119-124
  CrossrefPubMedGoogle Scholar
• 13 Miesbach W, Gilzinger A, Gökpinar B et al.. Prevalence of antiphospholipid antibodies in patients with neurological symptoms.  Clin Neurol Neurosurg. 2006;  108 135-142
  CrossrefPubMedGoogle Scholar
• 14 Tietjen G E, Day M, Norris L et al.. Role of anticardiolipin antibodies in young persons with migraine and transient neurological events.  Neurology. 1998;  50 1433-1440
  CrossrefPubMedGoogle Scholar
• 15 Silvestrini M, Matteis M, Troisi E et al.. Migrainous stroke and the antiphospholipid antibodies.  Eur Neurol. 1994;  34 316-319
  CrossrefPubMedGoogle Scholar
• 16 Carhuapoma J R, Mitsia P, Levine S R. Cerebral venous thrombosis and anticardiolipin antibodies.  Stroke. 1997;  28 2363-2369
  PubMedGoogle Scholar
• 17 Cuadrado M J, Khamashta M A, Ballesteros A et al.. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.  Medicine. 2000;  79 57-68
  CrossrefPubMedGoogle Scholar
• 18 Chapman J, Cohen-Armin M, Shoenfeld Y et al.. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.  Lupus. 1999;  8 127-133
  CrossrefPubMedGoogle Scholar
• 19 Shoenfeld Y, Lev S, Blatt I et al.. Features associated with epilepsy in the antiphospholipid syndrome.  J Rheumatol. 2004;  31 1344-1348
  PubMedGoogle Scholar
• 20 Cimaz R, Meroni P L, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome).  Lupus. 2006;  15 191-197
  CrossrefPubMedGoogle Scholar
• 21 Asherson R A, Derksen R H, Harris E N et al.. Chorea in systemic lupus erythematosus and “lupus-like” disease: association with antiphospholipid antibodies.  Semin Arthritis Rheum. 1987;  16 253-259
  CrossrefPubMedGoogle Scholar
• 22 Cervera R, Asherson R A, Font J et al.. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature.  Medicine. 1997;  76 203-212
  CrossrefPubMedGoogle Scholar
• 23 Asherson R A, Mercey D, Phillips G et al.. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies.  Ann Rheum Dis. 1987;  46 605-611
  CrossrefPubMedGoogle Scholar
• 24 Hanly J G, Hong C, Smith S et al.. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus.  Arthritis Rheum. 1999;  42 728-734
  CrossrefPubMedGoogle Scholar
• 25 Menon S, Jameson-Shortall E, Newman S P et al.. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus.  Arthritis Rheum. 1999;  42 735-741
  CrossrefPubMedGoogle Scholar
• 26 Schmidt R, Auer-Grumbach P, Fazekas F et al.. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings.  Stroke. 1995;  26 749-754
  CrossrefPubMedGoogle Scholar
• 27 Inzelberg R, Bornstein N M, Reider I et al.. The lupus anticoagulant and dementia in non-SLE patients.  Dementia. 1992;  3 140-145
  PubMedGoogle Scholar
• 28 Levine S R, Salowich-Palm L, Sawaya K L et al.. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.  Stroke. 1997;  28 1660-1665
  CrossrefPubMedGoogle Scholar
• 29 Nomura H, Hirashima Y, Endo S et al.. Anticardiolipin antibody aggravates cerebral vasospasm after subarachnoid hemorrhage in rabbits.  Stroke. 1998;  29 1014-1018
  PubMedGoogle Scholar
• 30 Levine S R, Brey R L. Neurological aspects of antiphospholipid antibody syndrome.  Lupus. 1996;  5 347-353
  PubMedGoogle Scholar
• 31 Caronti B, Calderaro C, Alessandri C et al.. Serum anti-β2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells.  J Autoimmun. 1998;  11 425-429
  CrossrefPubMedGoogle Scholar
• 32 Ziporen L, Shoenfeld Y, Levy Y et al.. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies.  J Clin Invest. 1997;  100 613-619
  CrossrefPubMedGoogle Scholar
• 33 Kent M N, Alvarez F J, Ng A K, Rote N S. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain.  Exp Neurol. 2000;  163 173-179
  CrossrefPubMedGoogle Scholar

Wolfgang MiesbachM.D. 

Medical Clinic III, Institute of Transfusion Medicine, Johann Wolfgang Goethe University

Frankfurt/Main, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany

Email: wolfgang.miesbach@kgu.de